Ultragenyx (RARE) Q1 2025 earnings summary

Executive summary

• Achieved strong Q1 2025 revenue growth of $139–$139.3 million, up 28% year-over-year, driven by commercial execution, Crysvita's international expansion, and new launches for Evkeeza.

• Net loss for Q1 2025 was $151–$151.1 million ($1.57 per share), an improvement from Q1 2024, reflecting higher revenues and moderated R&D expenses.

• Advanced multiple late-stage clinical programs, with key regulatory milestones on track for UX111, DTX401, and pivotal data readouts expected in 2025.

• Focused on rare disease treatments with four commercial products and the largest clinical pipeline in rare disease, including three anticipated near-term approvals.

• Cash, cash equivalents, and marketable securities totaled $563–$563.0 million as of March 31, 2025, supporting operations for at least the next 12 months.

Financial highlights

• Q1 2025 revenue reached $139–$139.3 million, up 28% year-over-year; product sales increased 46% to $91.5 million, with Crysvita contributing $103 million (25% growth), Dojolvi $17 million, Evkeeza $11 million, and Mepsevii $8 million.

• Royalty revenue rose 3% to $47.8 million, primarily from Crysvita sales in the U.S., Canada, and Europe.

• Net loss for the quarter was $151–$151.1 million, or $1.57 per share.

• Cash, cash equivalents, and marketable securities totaled $563–$563.0 million as of March 31, 2025.

• Operating expenses for Q1 2025 were $282 million, including $166 million R&D and $88 million SG&A.

Outlook and guidance

• Reaffirmed 2025 revenue guidance of $640–$670 million, representing 14–20% growth over 2024; Crysvita revenue expected between $460–$480 million, Dojolvi $90–$100 million.

• Net cash used in operations expected to decrease in subsequent quarters, with a pathway to full-year GAAP profitability in 2027.

• Key 2025 milestones include Phase 3 data for UX143, Aspire enrollment for GTX-102, BLA submission for DTX401, and PDUFA date for UX111.

• Expense management and focus on commercial launches expected to reduce net cash used in operations for 2025.

• Sufficient capital resources projected to fund operations for at least the next 12 months; additional capital may be sought for further expansion.